(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
Idiopathic pulmonary fibrosis (IPF), the most common phenotype of IIPs ... than those who do not to suffer from coronary ...
Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...
Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.
Research collaboration to leverage Surrozen's antibody research capabilities and expertise to discover a potential first in class <a target=_blank ...
The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback